David Luther

Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom.

Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom.

FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland.

GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California.

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Part of Princeton American Corp., GSK Products, Inc. is a beauty and barber supply concern. The company is based in Phoenix, AZ.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

PharmaKodex Ltd. develops pharmaceuticals products. It uses oral and transdermal drug delivery technologies to develop improved medicinal products. It develops and commercializes its products and technologies in an overlapping two component process. The company was founded in 2005 and is headquartered in Chippenham, UK

Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom.

F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom.

F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.

7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.

Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom.

Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom.

Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

NYU Elaine A. & Kenneth G. Langone Medical Center provides health care services. It offers treatments for bone, joint, and muscle disorders; brain and nervous system disorders cancers, tumors and blood disorders; genetic and chromosomal disorders and immune system disorders. The company was founded in 1841 and is headquartered in New York, NY.

Part of GSK Plc, SmithKline Beecham Pharmaceuticals Co. is a company that manufactures drugs and vaccines. The company is based in Philadelphia, PA.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland.